DSpace Repository

Pharmacogenetic assessment of tafenoquine efficacy in patients with Plasmodium vivax malaria

Show simple item record

dc.contributor.author St Jean, P.L.
dc.contributor.author Koh, G.C.K.W.
dc.contributor.author Breton, J.J.
dc.contributor.author Espino, F.E.J.
dc.contributor.author Hien, T.T.
dc.contributor.author Krudsood, S.
dc.contributor.author Lacerda, M.V.G.
dc.contributor.author Llanos-Cuentas, A.
dc.contributor.author Lon, C.
dc.contributor.author Mohammed, R.
dc.contributor.author Namaik-Larp, C.S.
dc.contributor.author Pereira, D.B.
dc.contributor.author Saunders, D.L.
dc.contributor.author Velez, I.D.
dc.contributor.author Yilma, D.
dc.contributor.author Villegas, M.F.
dc.contributor.author Duparc, S.
dc.contributor.author Green, J.A.
dc.date.accessioned 2020-12-14T16:10:15Z
dc.date.available 2020-12-14T16:10:15Z
dc.date.issued 2020
dc.identifier.uri https://hdl.handle.net/20.500.12866/8815
dc.description.abstract Plasmodium vivax has the largest geographic range of human malaria species and is challenging to manage and eradicate due to its ability to establish a dormant liver stage, the hypnozoite, which can reactivate leading to relapse. Until recently, the only treatment approved to kill hypnozoites was the 8-aminoquinoline, primaquine, requiring daily treatment for 14 days. Tafenoquine, an 8-aminoquinoline single-dose treatment with activity against P. vivax hypnozoites, has recently been approved by the US Food and Drug Administration and Australian Therapeutic Goods Administration for the radical cure of P. vivax malaria in patients 16 years and older. We conducted an exploratory pharmacogenetic analysis (GSK Study 208099) to assess the role of host genome-wide variation on tafenoquine efficacy in patients with P. vivax malaria using data from three GSK clinical trials, GATHER and DETECTIVE Part 1 and Part 2. Recurrence-free efficacy at 6 and 4 months and time to recurrence up to 6 months postdosing were analyzed in 438 P. vivax malaria patients treated with tafenoquine. Among the approximately 10.6 million host genetic variants analyzed, two signals reached genome-wide significance (P value ≤ 5 × 10-8). rs62103056, and variants in a chromosome 12 intergenic region, were associated with recurrence-free efficacy at 6 and 4 months, respectively. Neither of the signals has an obvious biological rationale and would need replication in an independent population. This is the first genome-wide association study to evaluate genetic influence on response to tafenoquine in P. vivax malaria. en_US
dc.language.iso eng
dc.publisher Wolters Kluwer Health
dc.relation.ispartof urn:issn:1744-6880
dc.rights info:eu-repo/semantics/restrictedAccess
dc.rights.uri https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.subject UNAVAILABLE en_US
dc.title Pharmacogenetic assessment of tafenoquine efficacy in patients with Plasmodium vivax malaria en_US
dc.type info:eu-repo/semantics/article
dc.identifier.doi https://doi.org/10.1097/FPC.0000000000000407
dc.subject.ocde https://purl.org/pe-repo/ocde/ford#3.02.00 es_PE
dc.subject.ocde https://purl.org/pe-repo/ocde/ford#1.06.07
dc.subject.ocde https://purl.org/pe-repo/ocde/ford#1.06.03


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

info:eu-repo/semantics/restrictedAccess Except where otherwise noted, this item's license is described as info:eu-repo/semantics/restrictedAccess

Search DSpace


Browse

My Account

Statistics